Stress, winter depression, RFK Jr., Sholto David: Morning Rounds

2 3 minutes read

RFK Jr. Continues to Push Forward

Since taking on the role of health secretary, Robert F. Kennedy Jr. has been implementing significant changes within his department. Despite facing obstacles such as legal battles over staff reductions and delays in establishing a chronic disease-focused agency, Kennedy remains steadfast in his efforts to reshape the health sector. According to former HHS assistant secretary Melanie Egorin, Kennedy’s approach has been insular, bypassing traditional channels for policy decisions.

Learn more about Kennedy’s progress, challenges, and potential opposition from lawmakers in 2026 in an in-depth report by STAT’s Chelsea Cirruzzo.

Two Rare Diseases Added to Newborn Screening Recommendations

In a recent announcement, Kennedy revealed that Duchenne muscular dystrophy and metachromatic leukodystrophy (MLD) have been included in the list of conditions states should screen newborns for. This decision comes after the disbandment of the expert committee responsible for reviewing new diseases, causing delays in the process.

Despite the setbacks, advocates view this development as a crucial step towards early detection and treatment. Read more about the journey to add these diseases to the screening list in a detailed analysis by STAT’s Jason Mast.

A Breakthrough in Antibiotic Development

Breaking the cycle of ineffective treatments for gonorrhea, the FDA recently approved two groundbreaking antibiotics with novel mechanisms of action. These new drugs offer hope against drug-resistant strains of the common STI, marking a significant advancement in the field of antibiotic research.

In a compelling First Opinion piece, Manica Balasegaram, the executive director of the Global Antibiotic Research & Development Partnership (GARDP), discusses the innovative not-for-profit model that facilitated the development of one of these antibiotics. Balasegaram emphasizes the collaborative nature of this approach and its potential to benefit all stakeholders. Discover more about GARDP’s mission to make these new treatments accessible globally in her insightful essay.

Scientific Brain Drain from the U.S.

As political turmoil continues to affect scientific research in the U.S., some scientists are considering leaving the country. The Trump administration’s policies have raised concerns about funding and immigration, prompting researchers like Pleuni Pennings to explore opportunities abroad.

While the extent of this “brain drain” remains uncertain, there is evidence of a growing trend among scientists seeking more stable environments for their work. Dive into STAT’s Andrew Joseph’s analysis of the reasons driving scientists to consider relocating and the potential impact on American science.

Stress and Cardiovascular Risk in Mental Health Disorders

New research suggests that individuals with anxiety and depression face a heightened risk of cardiovascular disease due to the impact of chronic stress on the body. The study, published in Circulation: Cardiovascular Imaging, highlights the interconnectedness of emotional well-being and heart health.

By examining the physiological responses to stress in individuals with anxiety and depression, researchers aim to uncover potential treatment strategies to mitigate cardiovascular risks. The findings underscore the importance of addressing emotional health alongside traditional heart disease prevention methods. Learn more about the study’s implications in a comprehensive report by STAT’s Elizabeth Cooney.

Science Whistleblower Receives Settlement

Sholto David, a science whistleblower, recently secured a $2.63 million settlement as part of a larger agreement related to misrepresented data in cancer research. David’s diligence in uncovering research misconduct led to a significant financial reward and raised awareness about the importance of scientific integrity.

Explore the details of David’s journey and the impact of his actions in a compelling report by Jonathan Wosen.